Literature DB >> 32890059

A Theoretical Paradigm for Evaluating Risk-Benefit of Status Epilepticus Treatment.

Edilberto Amorim1,2,3,4, Chris M McGraw3, M Brandon Westover3.   

Abstract

Aggressive treatment of status epilepticus with anesthetic drugs can provide rapid seizure control, but it might lead to serious medical complications and worse outcomes. Using a decision analysis approach, this concise review provides a framework for individualized decision making about aggressive and nonaggressive treatment in status epilepticus. The authors propose and review the most relevant parameters guiding the risk-benefit analysis of treatment aggressiveness in status epilepticus and present real-world-based case examples to illustrate how these tools could be used at the bedside and serve to guide future research in refractory status epilepticus treatment.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32890059      PMCID: PMC7516305          DOI: 10.1097/WNP.0000000000000753

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.590


  59 in total

Review 1.  Ictal-interictal continuum: A proposed treatment algorithm.

Authors:  Valia Rodríguez; Meghan F Rodden; Suzette M LaRoche
Journal:  Clin Neurophysiol       Date:  2016-02-11       Impact factor: 3.708

2.  Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Peter Fuhr; Peter W Kaplan; Stephan Rüegg
Journal:  Neurology       Date:  2013-12-06       Impact factor: 9.910

3.  Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus.

Authors:  Marina Gaínza-Lein; Iván Sánchez Fernández; Michele Jackson; Nicholas S Abend; Ravindra Arya; J Nicholas Brenton; Jessica L Carpenter; Kevin E Chapman; William D Gaillard; Tracy A Glauser; Joshua L Goldstein; Howard P Goodkin; Kush Kapur; Mohamad A Mikati; Katrina Peariso; Robert C Tasker; Dmitry Tchapyjnikov; Alexis A Topjian; Mark S Wainwright; Angus Wilfong; Korwyn Williams; Tobias Loddenkemper
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

Review 4.  Molecular and cellular mechanisms of pharmacoresistance in epilepsy.

Authors:  Stefan Remy; Heinz Beck
Journal:  Brain       Date:  2005-11-29       Impact factor: 13.501

5.  Untangling operational failures of the Status Epilepticus Severity Score (STESS).

Authors:  Raoul Sutter; Saskia Semmlack; Petra Opić; Rainer Spiegel; Gian Marco De Marchis; Sabina Hunziker; Peter W Kaplan; Stephan Rüegg; Stephan Marsch
Journal:  Neurology       Date:  2019-03-27       Impact factor: 9.910

6.  Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus.

Authors:  Dorothy M Jones; Nadia Esmaeil; Stephen Maren; Robert L Macdonald
Journal:  Epilepsy Res       Date:  2002-08       Impact factor: 3.045

7.  Epilepsy surgery for pharmacoresistant temporal lobe epilepsy: a decision analysis.

Authors:  Hyunmi Choi; Randall L Sell; Leslie Lenert; Peter Muennig; Robert R Goodman; Frank G Gilliam; John B Wong
Journal:  JAMA       Date:  2008-12-03       Impact factor: 56.272

8.  Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus.

Authors:  D C Hesdorffer; G Logroscino; G Cascino; J F Annegers; W A Hauser
Journal:  Ann Neurol       Date:  1998-12       Impact factor: 10.422

9.  Nonconvulsive status epilepticus in the emergency room.

Authors:  P W Kaplan
Journal:  Epilepsia       Date:  1996-07       Impact factor: 5.864

10.  Brexanolone as adjunctive therapy in super-refractory status epilepticus.

Authors:  Eric S Rosenthal; Jan Claassen; Mark S Wainwright; Aatif M Husain; Henrikas Vaitkevicius; Shane Raines; Ethan Hoffmann; Helen Colquhoun; James J Doherty; Stephen J Kanes
Journal:  Ann Neurol       Date:  2017-09-11       Impact factor: 10.422

View more
  1 in total

Review 1.  Electroencephalogram in the intensive care unit: a focused look at acute brain injury.

Authors:  Ayham Alkhachroum; Brian Appavu; Benjamin Rohaut; Jan Claassen; Satoshi Egawa; Brandon Foreman; Nicolas Gaspard; Emily J Gilmore; Lawrence J Hirsch; Pedro Kurtz; Virginie Lambrecq; Julie Kromm; Paul Vespa; Sahar F Zafar
Journal:  Intensive Care Med       Date:  2022-08-23       Impact factor: 41.787

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.